Skip to content
Screener

Celcuity CELC Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Gilead Sciences logo
Gilead SciencesGILD
$49.36B-11.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.37B+55.5%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$967.46M+32.7%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$436.76M+79.8%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.55B+150%
Enterprise value$4.54B+142%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Celcuity’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-023180
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 6)--
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized as of March 31, 2026, and December 31, 2025; 0 shares issued and outstanding as of March 31, 2026, and December 31, 2025
Common stock, $0.001 par value; 95,000,000 shares authorized as of March 31, 2026, and December 31, 2025; 48,347,390 and 48,244,960 shares issued and outstanding as of March 31, 2026, and December 31, 2025, respectively4848
Additional paid-in capital555,215549,404
Accumulated deficit(501,738)(448,897)
Total stockholders’ equity53,525100,555
Total liabilities and stockholders’ equity$410,164$466,558

Item 1. Financial Statements (unaudited) ITEM

FAQ

What is Celcuity's total liabilities & equity?
Celcuity (CELC) reported total liabilities & equity of $410.16M in Q1 2026.
How has Celcuity's total liabilities & equity changed year-over-year?
Celcuity's total liabilities & equity increased by 88.0% year-over-year, from $218.13M to $410.16M.
What is the long-term trend for Celcuity's total liabilities & equity?
Over 5 years (2020 to 2025), Celcuity's total liabilities & equity has grown at a 104.8% compound annual growth rate (CAGR), from $12.96M to $466.56M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Celcuity's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude